The Official MicroCap News Source
Watchlist News
Please Login or Register to view News Stories

Healthcare & Insurance

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins, today announced

Thursday, June 24, 2021

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Biosimulation Software for Evaluating Regulatory

The PMDA enters 8th consecutive year of using Certara’s biosimulation softwarePRINCETON, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s

Wednesday, June 23, 2021

Neuronetics Set to Join Russell 2000® Index

MALVERN, Pa., June 23, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that the

Wednesday, June 23, 2021

HCI Group to Present at BofA Securities 2021 InsurTech Conference on June 30, 2021

TAMPA, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE: HCI), a leading homeowners insurer executing on a nationwide expansion plan through its technology-led insurance subsidiary TypTap Insurance Company, will participate at the BofA Securities 2021 InsurTech Conference, which will

Wednesday, June 23, 2021

GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association

Study highlights the clinical performance of NIS4® technology in diagnosing at-risk NASH in patients with type 2 diabetes irrespective of age compared to other non-invasive testsNew analyses show the potential of NIS4® technology to be a valuable clinical tool either alone or in sequential

Wednesday, June 23, 2021

Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee

FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of

Wednesday, June 23, 2021

Pacific Biosciences and Rady Children’s Institute for Genomic Medicine Announce its First Research Collaboration for Whole Genome Sequencing

HiFi Sequencing will be used on a cohort of rare disease cases with the aim to identify numerous variants, both small and structural, that are not readily detectable by short-read sequencingMENLO PARK, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:

Wednesday, June 23, 2021

AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials

GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today

Wednesday, June 23, 2021

Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for

CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the

Wednesday, June 23, 2021

Ozop Energy Solutions OZSC Signs Global Crypto Climate Accord

CCA Signatories commit to support the crypto industry’s transition to net zero greenhouse gas emissions by 2040, and achieving net-zero emissions from electricity consumption by 2030 WARWICK, NY, June 23, 2021 (GLOBE NEWSWIRE) -- Ozop Energy Solutions (OZSC), (“Ozop” or the

Wednesday, June 23, 2021

Tecan expands its commercial reach, its capabilities and its US and Asia presence with the acquisition of Paramit Corporation

Tecan to acquire Paramit Corporation, a leading OEM developer and manufacturer of medical devices and life sciences instruments, for a total consideration of USD 1.0 billion (CHF 920 million) In full year 2021, Paramit is expected to generate around USD 280m in sales (CHF 257m) and around USD 50m

Wednesday, June 23, 2021

Milestone Scientific Expands Medical Sales Team to Capitalize on Growing Interest in CompuFlo Including Appointment of Senior Industry Sales

ROSELAND, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has expanded its medical sales team including the appointment of Chet

Wednesday, June 23, 2021

DEINOVE- Adoption of all the ordinary resolutions at the Shareholders’ Meeting of June 21, 2021

DEINOVE- Adoption of all the ordinary resolutions at the Shareholders’ Meeting of June 21, 2021 The Extraordinary Shareholders’ Meeting will be convened on third notice at a later date DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and

Wednesday, June 23, 2021

Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021

For informationNicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021June 23, 2021Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced that results from the Dolomites

Wednesday, June 23, 2021

Valneva Announces Successful Outcome of its AGM

Saint-Herblain (France), June 23, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced today that all the resolutions

Wednesday, June 23, 2021

HUTCHMED Announces Pricing of Global Offering

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the pricing of its global offering (the “Global Offering”) of 104,000,000 new ordinary shares (the “Offer

Wednesday, June 23, 2021

Tauriga Sciences, Inc. Appoints Colorado-based Orthopedic Surgeon, Dr. Craig Loucks, as Member of the Company’s Advisory Board

NEW YORK, NY, June 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced the appointment of Dr. Craig Loucks (“Dr. Loucks”) as a member of the

Wednesday, June 23, 2021

Optimi Health Engages U.S. Based Law Firm for Patent Support

VANCOUVER, British Columbia, June 23, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products today announced that Thomas Finetti, partner at Charney IP Law, has been engaged to

Wednesday, June 23, 2021

Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11

-- Initiation of the ABILITY Study, a first-in-human trial, is expected in the third quarter of 2021 -- Trial is designed to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors -- Preliminary update on safety,

Wednesday, June 23, 2021

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma

NEW YORK, June 23, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Wednesday, June 23, 2021

loading

© 2021 Stock News Now